

Hogan
Lovells

China Drug Administration publishes a key Draft Guidance on data exclusivity for pharmaceuticals

08 May 2018

Pharmaceutical and Biotechnology Alert

This is the first time the China Drug Administration (CDA) provides details on how the data exclusivity applies to pre-clinical and clinical data submitted to the agency. Companies with plans to launch pharmaceutical products in China should carefully review the Draft Guidance and assess its implications.

Read more: [China Drug Administration publishes a key Draft Guidance on data exclusivity for pharmaceuticals](#)

Contacts



Philip Katz

Partner



Xin Tao

Senior
Associate

> [Read the full article online](#)